Critical Analysis: Cardio Diagnostics (NASDAQ:CDIO) and Genmab A/S (NASDAQ:GMAB)

Cardio Diagnostics (NASDAQ:CDIO) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Profitability

This table compares Cardio Diagnostics and Genmab A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%
Genmab A/S	19.08%	14.89%	7.73%

Insider and Institutional Ownership

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 9.0% of Cardio Diagnostics shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Cardio Diagnostics and Genmab A/S”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$14,450.00	362.57	-$6.50 million	($2.92)	-0.61
Genmab A/S	$3.72 billion	6.64	$963.00 million	$1.27	31.16

Genmab A/S has higher revenue and earnings than Cardio Diagnostics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cardio Diagnostics has a beta of 2.29, suggesting that its share price is 129% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Cardio Diagnostics and Genmab A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1	0	0	0	1.00
Genmab A/S	0	3	9	1	2.85

Genmab A/S has a consensus target price of $43.39, indicating a potential upside of 9.65%. Given Genmab A/S’s stronger consensus rating and higher probable upside, analysts plainly believe Genmab A/S is more favorable than Cardio Diagnostics.

Summary

Genmab A/S beats Cardio Diagnostics on 11 of the 15 factors compared between the two stocks.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.